Skip to main content

VistaGen Therapeutics, Inc. (VTGN) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $0.63 (+2.71%)

Consensus Target
$0.95
Upside
+50.8%
Analysts
3
Rating
Hold(3.00)

Price Target Range

Low $0.90Consensus $0.95High $1.00
▲ Current $0.63

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Dec 17, 2025Andrew TsaiJefferies$0.90+42.9%
Nov 17, 2025Paul MattheisStifel Nicolaus$12.00+1804.8%
Jul 22, 2022Andrew TsaiJefferies$6.00+852.4%

VTGN vs Sector & Market

MetricVTGNHealthcare AvgLarge Cap Avg
Analyst Rating3.002.242.41
Analyst Count3818
Target Upside+50.8%+1150.2%+14.9%
P/E Ratio-0.386.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2027-03-31$1M$1M$1M3
2028-03-31$7M$7M$7M3
2029-03-31$20M$20M$20M2
2030-03-31$80M$80M$80M1

EPS Estimates

PeriodLowAvgHigh#
2027-03-31$-1.19$-1.10$-1.003
2028-03-31$-2.33$-1.53$-1.033
2029-03-31$-3.67$-0.74$2.192
2030-03-31$-0.56$-0.56$-0.561

Frequently Asked Questions

What is the analyst consensus for VTGN?

The consensus among 3 analysts covering VistaGen Therapeutics, Inc. (VTGN) is Hold with an average price target of $0.95.

What is the highest price target for VTGN?

The highest price target for VTGN is $12.00, set by Paul Mattheis at Stifel Nicolaus on 2025-11-17.

What is the lowest price target for VTGN?

The lowest price target for VTGN is $0.90, set by Andrew Tsai at Jefferies on 2025-12-17.

How many analysts cover VTGN?

3 analysts have issued ratings for VistaGen Therapeutics, Inc. in the past 12 months.

Is VTGN a buy or sell right now?

Based on 3 analyst ratings, VTGN has a consensus rating of Hold (3.00/5) with a +50.8% upside to the consensus target of $0.95.

What are the earnings estimates for VTGN?

Analysts estimate VTGN will report EPS of $-1.10 for the period ending 2027-03-31, with revenue estimated at $1M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.